Clinical trials: Alopecia Areata
Alopecia Universalis (AU), Alopecia Totalis (AT)
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
- Trial name
- NCT03315689
- Testing
- Vehicle, ATI-50002
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aclaris Therapeutics, Inc.
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05417308
- Testing
- Minoxidil, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
The purpose of this study is to evaluate the efficacy and safety of SHAPE Gel applied topically to adult patients with alopecia areata of the scalp.
- Trial name
- NCT02636244
- Testing
- SHAPE Gel
- Volunteers
- 40 people
- Sponsor
- TetraLogic Pharmaceuticals
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Breast Cancer, Metastatic Breast Cancer
Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer
HALACAP-1406 is a prospective single-centre non-interventional study assessing the refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®) in the conditions of use specified in its marketing…
- Trial name
- NCT02863146
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Oscar Lambret
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
- Conditions
- Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
- Trial name
- NCT06501924
- Testing
- DA-005, Topical minoxidil 5%, DA-002
- Volunteers
- 516 people
- Sponsor
- Applied Biology, Inc.
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Androgenetic Alopecia, Alopecia
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
The purpose of this study is to evaluate the clinical efficacy of platelet rich plasma (PRP) injections for non-scaring alopecia in women.
- Trial name
- NCT03689452
- Testing
- Platelet Rich Plasma, Normal saline
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03941548
- Testing
- CTP-543
- Where
- 12 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Concert Pharmaceuticals
Alopecia
Hairstetics Hair Implant Device Safety and Efficacy
This is a prospective, single-arm, multi-center, international, open-label, non-randomized, clinical study. The aim of the study is to assess the safety and efficacy of the use of the Hairstetics hair implant device in subjects…
- Trial name
- NCT02856308
- Testing
- Hairstetics hair implant device
- Where
- 8 sites in France, India and 2 more
- Volunteers
- 100 people
- Sponsor
- Hairstetics
Alopecia Areata, Janus Kinase Inhibitors
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing.
- Trial name
- NCT06573593
- Testing
- Tofacitinib, Baricitinib, Ruxolitinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hair Loss
For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers
This study is to evaluate differences in the gut and follicle/scalp microbiome signature in AGA compared to a non-AGA population.
- Trial name
- NCT07716748
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Skin Centre
Alopecia, Androgenetic
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
The primary objective of this study is to evaluate the safety and feasibility of the Celution and Puregraft Systems in the processing and preparation of an autologous fat graft enriched with adipose-derived regenerative cells…
- Trial name
- STYLE (NCT02503852)
- Testing
- Puregraft System, Celution System, Kerastem Therapy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Kerastem Technologies, LLC